Price Alert

TriSalus Life Sciences In... (TLSI)

NASDAQ: TLSI · Real-Time Price · USD

4.86

0.31 (6.81%)

At close: Aug 18, 2025, 3:59 PM

4.95

1.96%

After-hours: Aug 18, 2025, 04:17 PM EDT

6.81% (1D)

Bid	3.84
Market Cap	184.37M
Revenue (ttm)	32.14M
Net Income (ttm)	-27.21M
EPS (ttm)	-1.15
PE Ratio (ttm)	-4.22
Forward PE	-23.29
Analyst	Buy

Ask	4.99
Volume	104,906
Avg. Volume (20D)	90,608
Open	4.60
Previous Close	4.55
Day's Range	4.55 - 4.95
52-Week Range	3.42 - 5.99
Beta	0.48

About TLSI

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TLSI

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for TLSI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

TriSalus Life Sciences has released their quartely earnings on Aug 12, 2025:

Revenue of $11.21M exceeds estimates by $545.43K, with 52.27% YoY growth.

EPS of -0.27 misses estimates by -0.05, with -28.57% YoY decline.

Next Earnings Release

TriSalus Life Sciences Inc. is scheduled to release its earnings on Nov 13, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

9 months ago

-10.89%

TriSalus Life Sciences shares are trading lower af... Unlock content with Pro Subscription

News

6 days ago · seekingalpha.com

TriSalus Life Sciences, Inc. (TLSI) Q2 2025 Earnings Call Transcript

TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 AM ET Company Participants David B. Patience - Chief Financial Officer Jeremy Feffer - Corporate Parti...

6 days ago · zacks.com

TriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue Estimates

TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.21 per share a year ago.

1 week ago · businesswire.com

TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapie...

2 weeks ago · businesswire.com

TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), a company working to improve outcomes for patients with solid tumors by combining innova...

3 weeks ago · businesswire.com

TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), a company working to improve outcomes for patients with solid tumors by combining innova...

3 weeks ago · businesswire.com

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company focused on improving outcomes for patients with solid tumors, announced the completion of its previously dis...

1 month ago · businesswire.com

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, current on...

2 months ago · businesswire.com

TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative deli...

2 months ago · businesswire.com

TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies and its investigational ...